{"id":"atorvastatin-lipilou","safety":{"commonSideEffects":[{"rate":"1–3","effect":"Muscle pain or myalgia"},{"rate":"1–3","effect":"Elevated liver enzymes (ALT/AST)"},{"rate":"1–2","effect":"Headache"},{"rate":"<0.1","effect":"Rhabdomyolysis (rare)"},{"rate":"1–2","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking HMG-CoA reductase, atorvastatin decreases hepatic cholesterol production and upregulates LDL receptors on liver cells, enhancing clearance of LDL cholesterol from circulation. This leads to reduced plasma LDL-C levels and improved lipid profiles, lowering cardiovascular risk.","oneSentence":"Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels in the blood.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:52.081Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia"},{"name":"Primary and secondary prevention of cardiovascular disease"},{"name":"Reduction of risk of myocardial infarction and stroke"}]},"trialDetails":[{"nctId":"NCT04511000","phase":"PHASE4","title":"Clinical Trial to to Compare of the Efficacy and Safety of Lipilou® 20 mg and Lipilou® 10 mg","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2017-10-11","conditions":"Hypercholesterolemia","enrollment":250},{"nctId":"NCT01956201","phase":"PHASE3","title":"Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin","status":"UNKNOWN","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2013-12","conditions":"Mixed Hyperlipidemia","enrollment":476},{"nctId":"NCT01029522","phase":"PHASE4","title":"Dyslipidemia in Cardiovascular Disease","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2008-08","conditions":"Dyslipidemia","enrollment":244}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Atorvastatin (Lipilou)","genericName":"Atorvastatin (Lipilou)","companyName":"Chong Kun Dang Pharmaceutical","companyId":"chong-kun-dang-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels in the blood. Used for Hypercholesterolemia and dyslipidemia, Primary and secondary prevention of cardiovascular disease, Reduction of risk of myocardial infarction and stroke.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}